盐酸凯普拉生片治疗反流性食管炎的成本-效果OA

Objective To evaluate the effectiveness and economy of kenuolazan hydrochloride tablets in the treatment of patients with reflux esophagitis(RE).Methods Using RE patients as the research subjects,from the perspective of medical insurance payer,we construct a Markov model to simulate the health utility and direct medical costs under each reference regimen,evaluating the economy of kenuolazan regimen compared to vonoprazan regimen in the treatment of reflux esophagitis based on the Incremental Cost-effectiveness Ratio(ICER),and sensitivity analysis was performed to verify the stability of the results.Results The total cost of the kenuolazan regimen was RMB 2 225.40 with total QALYs of 1.082 81,and the total cost of the vonoprazan regimen was RMB 2 340.78 with total QALYs of 1.082 40.The ICER was-280 500.50 RMB/QALY.The factors in the sensitivity analysis had no significant impact on the study findings.Conclusion In the treatment of RE patients,the kenuolazan regimen has a clear advantage over the vonoprazan regimen.